Saturday 17 October 2026
Export AVBP’s income statement to Excel — free account
ArriVent BioPharma, Inc.
AVBP Healthcare Biotechnology
In the quarter to June 2026, EPS fell 16.7% and free cash flow fell 51.5%, each against the same quarter a year earlier.
16.66
0.13
−0.77%
Follow AVBP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
14.90 | 12.83 | 13.95 | 14.16 |
Net Debt/EBITDA |
7.84 | 8.06 | 6.99 | 7.01 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.02 | 0.86 | 0.97 | 0.79 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.85) | (0.80) | (0.93) | (0.83) | |
Cash per Share |
7.16 | 8.13 | 7.24 | 7.84 | |
Shareholders Equity per Share |
7.28 | 7.99 | 7.19 | 7.71 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.28 | 7.99 | 7.19 | 7.71 | |
Free Cash Flow |
(35.80) | (30.66) | (41.89) | (39.58) | |
Working Capital |
299.66 | 306.95 | 323.71 | 366.33 | |
Net Current Asset Value |
299.66 | 306.95 | 323.39 | 366.30 | |
| Other line items | |||||
Quick Ratio |
13.93 | 12.06 | 13.06 | 13.40 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.85) | (0.80) | (0.93) | (0.83) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
5.29 | 4.86 | 6.55 | 3.14 | |
Average Assets |
309.63 | 304.06 | 282.40 | 332.11 | |
Average Common Equity |
291.25 | 282.44 | 263.26 | 308.36 |
Columns are period end dates